If you have been reading about Synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
== Further reading == Abbott, Andrew (2001). Chaos of Disciplines. University of Chicago Press. ISBN 978-0-226-00101-2. Oleson, Alexandra; Voss, John (1979). The Organization of knowledge in modern America, 1860–1920. Johns Hopkins University Press. ISBN 0-8018-2108-8. US Department of Education Institute of Education Sciences. Classification of Instructional Programs (CIP). National Center for Education Statistics.
In rational protein design, proteins can be redesigned from the sequence and structure of a known protein, or completely from scratch in de novo protein design. In protein redesign, most of the residues in the sequence are maintained as their wild-type amino-acid while a few are allowed to mutate. In de novo design, the entire sequence is designed anew, based on no prior sequence. Both de novo designs and protein redesigns can establish rules on the sequence space: the specific amino acids that are allowed at each mutable residue position. For example, the composition of the surface of the RSC3 probe to select HIV-broadly neutralizing antibodies was restricted based on evolutionary data and charge balancing. Many of the earliest attempts on protein design were heavily based on empiric rules on the sequence space. Moreover, the design of fibrous proteins usually follows strict rules on the sequence space. Collagen-based designed proteins, for example, are often composed of Gly-Pro-X repeating patterns. The advent of computational techniques allows designing proteins with no human intervention in sequence selection.
PCP can be ingested through smoking. "Fry" and "sherm" are street terms for marijuana or tobacco cigarettes that are dipped in PCP and then dried. PCP hydrochloride can be insufflated (snorted), depending upon the purity. This is most often referred to as "angel dust". An oral pill can also be compressed from the co-compounded powder form of the drug. This is usually referred to as "peace pill". The free base is hydrophobic and may be absorbed through skin and mucous membranes (often inadvertently). This form of the drug is commonly called "wack".
== Pharmacology == Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'. Mitomycin gel is an alkylating drug, meaning it inhibits the transcription of DNA into RNA, stopping protein synthesis and taking away the cancer cell's ability to multiply.
== Clinical significance == Leukotrienes, which require the FLAP protein to be synthesized, have an established pathological role in allergic and respiratory diseases. Animal and human genetic evidence suggests they may also have an important role in atherosclerosis, myocardial infarction, and stroke. The structure of FLAP provides a tool for the development of novel therapies for respiratory and cardiovascular diseases and for the design of focused experiments to probe the cell biology of FLAP and its role in leukotriene biosynthesis.
Sources: en.wikipedia.org
The ash content of a sample is a measure of the amount of inorganic noncombustible material it contains. The residues after a sample is completely burnt - in contrast to the ash remaining after incomplete combustion - typically consist of oxides of the inorganic elements present in the original sample. Ash is one of the components in the proximate analysis of biological materials, consisting mainly of salty, inorganic constituents. It includes metal salts which are important for processes requiring ions such as Na+ (sodium), K+ (potassium), and Ca2+ (calcium). It also includes trace minerals which are required for unique molecules, such as chlorophyll and hemoglobin. Procedures for ash content determination are similar to procedures for loss on ignition. Typically, the term ash is used for primarily organic material such as fuels and foodstuffs, while the term loss on ignition is used for primarily inorganic material such as rocks and combusted ash. A crucible can be used to determine the percentage of ash contained in a sample of material such as coal, wood, oil, rubber, plastics, foodstuffs, or any burnable material. The appropriate method for ash determination varies depending upon the type of sample analyzed. Each method may vary in parameters such as furnace temperature, residence time in the furnace, number of heating steps, and sample preparation procedures. The ISO mandates ash content determination for most foodstuffs. Examples include
== History == The name frappé ('punched', figuratively 'shaken') comes from French, and describes drinks chilled with ice. Beginning in the 19th century, a variety of cold coffee drinks named café frappé (à la glace) are documented, some similar to slushies and others more like iced coffee. It has been said that the Greek version of café frappé, using instant coffee, was invented in 1957 at the Thessaloniki International Fair. A representative of the Nestlé company, Giannis Dritsas, was exhibiting a new product for children. It was a chocolate beverage produced instantly by mixing it with milk and shaking it in a shaker. Dritsas' employee, Dimitris Vakondios, was looking for a way to have his usual instant coffee during his break but could not find any hot water, so, he mixed the coffee with cold water and ice cubes in a shaker. Nikos Bakounakis was the first to express doubts about this story in 2006, and further evidence was later presented by the magazine Gastronomos in 2013. Based on Nestlé’s newspaper advertisements from the period leading up to the 1957 Thessaloniki International Trade Fair, it appears that the product was already being promoted as "Nescafé frappe", either as coffee with ice cubes or as an iced shaken—as suggested by its name (frappé = shaken)—or stirred drink.
==== Orthodox Christian heritage ==== Among the first Christian missionaries to arrive in the Aleutian Islands was a party of ten Russian Orthodox monks and priests, who arrived in 1793. Within two years, a monk named Herman was the only survivor of that party. He settled on Spruce Island, near Kodiak Island, and often defended the rights of the Aleuts against the Russian trading companies. He is now known in the Orthodox Church as Saint Herman of Alaska. Another early Christian missionary of the Russian Orthodox Church was Father Veniaminov who arrived in Unalaska in 1824. He was named Bishop Innokentii in 1840 and moved to Sitka. He is now known in the Orthodox Church as Saint Innocent of Alaska. The principal settlements were on Unalaska Island. The oldest was Iliuliuk (also called Unalaska), settled in 1760–1775, with a customs house and an Orthodox church.
== Discovery == The N-acetylmuramoyl-L-alanine amidase enzymatic activity was first observed in human and mouse serum in 1981 by Branko Ladešić and coworkers. The enzyme (abbreviated NAMLAA) was then purified from human serum by this and other groups. The sequence of 15 N-terminal amino acids of NAMLAA was identified, but the cDNA for the protein was not cloned and the gene encoding NAMLAA was not known. In 2000, Dan Hultmark and coworkers discovered a family of 12 Peptidoglycan Recognition Protein (PGRP) genes in Drosophila melanogaster and by homology searches of available human and mouse sequences predicted the presence of long forms of human and mouse PGRPs, which they named PGRP-L by analogy to long forms of insect PGRPs. In 2001, Roman Dziarski and coworkers discovered and cloned three human PGRPs, named PGRP-L, PGRP-Iα, and PGRP-Iβ (for long and intermediate size transcripts), and established that human genome codes for a family of 4 PGRPs: PGRP-S (short PGRP) and PGRP-L, PGRP-Iα, and PGRP-Iβ. Subsequently, the Human Genome Organization Gene Nomenclature Committee changed the gene symbols of PGRP-S, PGRP-L, PGRP-Iα, and PGRP-Iβ to PGLYRP1 (peptidoglycan recognition protein 1), PGLYRP2 (peptidoglycan recognition protein 2), PGLYRP3 (peptidoglycan recognition protein 3), and PGLYRP4 (peptidoglycan recognition protein 4), respectively, and this nomenclature is currently also used for other mammalian PGRPs. Sergei Kiselev and coworkers also independently cloned mouse PGLYRP2 (which they named TagL).
Sources: en.wikipedia.org
== Function == The meprin alpha subunit product of the MEP1A gene is processed in the endoplasmic reticulum during intracellular transport, and is secreted as homomeric meprin A. Meprin alpha subunits may self-associate, and once secreted, form very large multimers, with a molecular mass of over 1 million daltons. In cells concurrently expressing MEP1B, the meprin alpha and meprin beta subunits form disulfide dimers that interact to form membrane bound heterotetrameric meprin A.
also helps. This can be done by lowering the column temperature in G.C., or by choosing a weaker mobile phase in L.C. (moderately effective) Changing α is the most effective way of increasing resolution. This can be done by choosing a stationary phase that has a greater difference between
==== Bridges ==== Albany has both the Ellsworth Street Bridge which was constructed in 1926 and the Lyon Street Bridge that was constructed in 1973. They are both two-lane bridges that make up part of U.S. Route 20. The two bridges connect Linn to the south with Benton county in the north as they pass across the Willamette River. this makes up the major connection of downtown Albany with the north end of town and to Corvallis.
=== Potential role in the oligomerization of Aβ === Recent studies have observed that the oligomerization of synthetic Aβ was completely inhibited by the competitive IDE substrate, insulin. These findings suggest that IDE activity is capable of joining of several Aβ fragments together. Qui et al. hypothesized that the Aβ fragments generated by IDE can either enhance oligomerization of the Aβ peptide or can oligomerize themselves. It is also entirely possible that IDE could mediate the degradation and oligomerization of Aβ by independent actions that have yet to be investigated.
== Catalyzed reaction == Tyrosinase carries out the oxidation of phenols such as tyrosine and dopamine using molecular oxygen (O2). In the presence of catechol, benzoquinone is formed (see reaction below). Hydrogens removed from catechol combine with oxygen to form water. The substrate specificity becomes dramatically restricted in mammalian tyrosinase which uses only L-form of tyrosine or DOPA as substrates, and has restricted requirement for L-DOPA as cofactor.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.